Dana Pizzuti Biography and Net Worth

Chief Medical and Development Officer of Crinetics Pharmaceuticals

Dana Pizzuti, M.D. is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, and medical and regulatory affairs.

Dr. Pizzuti joined Crinetics as chief development officer in 2022. Before joining Crinetics, Dr. Pizzuti served as senior vice president, development operations and chief medical officer at Ascendis Pharma, where she rebuilt the U.S. regulatory affairs unit into a streamlined global organization. At Ascendis, she led the company’s successful U.S. and European marketing applications for lonapegsomatropin, a combination drug-device product for children one year and older with growth hormone deficiency. Earlier in her career, Dr. Pizzuti established the regulatory affairs function at Rigel Pharmaceuticals, where she directed the team responsible for the company’s first new drug application approval. She also previously led the global regulatory affairs unit at Gilead Sciences, managing over 500 people across 33 countries, leading to marketing authorizations for 15 new drugs in global markets.

Dr. Pizzuti earned her Bachelor of Science (cum laude) in biology from Yale University, and she received her M.D. from the NYU School of Medicine. She completed her medical internship and residency at NYU-Bellevue Hospital Center in New York City and fellowship in infectious disease at Albert Einstein-Montefiore Medical Center.

What is Dana Pizzuti's net worth?: The estimated net worth of Dana Pizzuti is at least $1.53 million as of October 3rd, 2024. Dr. Pizzuti owns 28,507 shares of Crinetics Pharmaceuticals stock worth more than $1,527,975 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Pizzuti may own. Learn More about Dana Pizzuti's net worth.
How do I contact Dana Pizzuti?: The corporate mailing address for Dr. Pizzuti and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Dana Pizzuti's contact information.
Has Dana Pizzuti been buying or selling shares of Crinetics Pharmaceuticals?: Over the course of the past ninety days, Dana Pizzuti has sold $785,306.25 in Crinetics Pharmaceuticals stock. Most recently, Dana Pizzuti sold 14,375 shares of the business's stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $54.63, for a transaction totalling $785,306.25. Following the completion of the sale, the insider now directly owns 28,507 shares of the company's stock, valued at $1,557,337.41. Learn More on Dana Pizzuti's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 33 times. They sold a total of 554,549 shares worth more than $26,112,214.05. The most recent insider tranaction occured on November, 22nd when COO Jeff E Knight sold 501 shares worth more than $28,316.52. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 11/22/2024.

Dana Pizzuti Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2024	Sell	14,375	$54.63	$785,306.25	28,507
7/3/2024	Sell	14,375	$44.87	$645,006.25	28,507
6/24/2024	Sell	9,500	$45.73	$434,435.00	27,786
4/15/2024	Sell	14,375	$44.47	$639,256.25	27,786
3/20/2024	Sell	15,089	$44.06	$664,821.34	27,786
1/3/2024	Sell	14,375	$35.00	$503,125.00	5,911
12/21/2023	Sell	9,583	$34.57	$331,284.31	5,911
4/5/2023	Sell	8,212	$16.15	$132,623.80	4,500

Dana Pizzuti Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $53.60

$51.73

$54.25

50 Day Range

MA: $57.04

$52.09

$60.69

2 Week Range

Now: $53.60

$33.67

$62.53

Volume

1,940,449 shs

Average Volume

780,930 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.